Impact of breast cancer genetic testing in Brazilian patients: insights from the MAGENTA study
| dc.contributor.author | Evelin Scarelli | |
| dc.contributor.author | Carolina Meyn Teixeira | |
| dc.contributor.author | Nathália Viana e Silva | |
| dc.contributor.author | Andréa Silveira dos Santos Bredariol | |
| dc.contributor.author | Giovana Sivieri Baracho | |
| dc.contributor.author | Fabiano Hahn Souza | |
| dc.contributor.author | L. Holtz | |
| dc.coverage.spatial | Bolivia | |
| dc.date.accessioned | 2026-03-22T19:59:55Z | |
| dc.date.available | 2026-03-22T19:59:55Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | The survey respondents in Brazil comprised a highly educated and financially secure group of patients. Although not generalizable to the entire Brazilian population, our results revealed that even in a highly educated and well-informed cohort there is a strong association between age and income level with genetic testing. These findings expose the real-world challenges for increasing genetic testing coverage in Brazil, where testing is only warranted in the private health system, highlighting the need for health policies to increase test availability for lower income brackets. | |
| dc.identifier.doi | 10.3389/fonc.2025.1597891 | |
| dc.identifier.uri | https://doi.org/10.3389/fonc.2025.1597891 | |
| dc.identifier.uri | https://andeanlibrary.org/handle/123456789/79382 | |
| dc.language.iso | en | |
| dc.publisher | Frontiers Media | |
| dc.relation.ispartof | Frontiers in Oncology | |
| dc.source | AstraZeneca (Brazil) | |
| dc.subject | Genetic testing | |
| dc.subject | Medicine | |
| dc.subject | Cohort | |
| dc.subject | Breast cancer | |
| dc.subject | Test (biology) | |
| dc.subject | Oncology | |
| dc.subject | Hereditary Cancer | |
| dc.subject | Internal medicine | |
| dc.subject | Public health | |
| dc.subject | Cohort study | |
| dc.title | Impact of breast cancer genetic testing in Brazilian patients: insights from the MAGENTA study | |
| dc.type | article |